The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic

被引:187
作者
Blanchard, DC
Griebel, G
Blanchard, RJ
机构
[1] Univ Hawaii, Pacific Biomed Res Ctr, Honolulu, HI 96822 USA
[2] Univ Hawaii, John A Burns Sch Med, Dept Genet & Mol Biol, Honolulu, HI 96822 USA
[3] Sanofi Synthelabo, CNS Res Dept, Bagneux, France
[4] Univ Hawaii, Dept Psychol, Honolulu, HI 96822 USA
关键词
Mouse Defense Test Battery; anxiety; panic; GABA(A)-benzodiazepine receptor; 5-HT; (5-hydroxytryptamine; serotonin); neuropeptide;
D O I
10.1016/S0014-2999(03)01276-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Mouse Defense Test Battery was developed from tests of defensive behaviors in rats, reflecting earlier studies of both acute and chronic responses of laboratory and wild rodents to threatening stimuli and situations. It measures flight, freezing, defensive threat and attack, and risk assessment in response to an unconditioned predator stimulus, as well as pretest activity and postthreat (conditioned) defensiveness to the test context. Factor analyses of these indicate four factors relating to cognitive and emotional aspects of defense, flight, and defensiveness to the test context. In the Mouse Defense Test Battery, GABA(A)-benzodiazepine anxiolytics produce consistent reductions in defensive threat/attack and risk assessment, while panicolytic and panicogenic drugs selectively reduce and enhance, respectively, flight. Effects of GABA(A)-benzodiazepine, serotonin, and neuropeptide ligands in the Mouse Defense Test Battery are reviewed. This review suggests that the Mouse Defense Test Battery is a sensitive and appropriate tool for preclinical evaluation of drugs potentially effective against defense-related disorders such as anxiety and panic. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:97 / 116
页数:20
相关论文
共 188 条
  • [31] Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries
    Blanchard, RJ
    Griebel, G
    Henrie, JA
    Blanchard, DC
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (06) : 783 - 789
  • [32] BRADWEJN J, 1994, ARCH GEN PSYCHIAT, V51, P486
  • [33] EFFECT OF CI-988 ON CHOLECYSTOKININ TETRAPEPTIDE-INDUCED PANIC SYMPTOMS IN HEALTHY-VOLUNTEERS
    BRADWEJN, J
    KOSZYCKI, D
    PARADIS, M
    REECE, P
    HINTON, J
    SEDMAN, A
    [J]. BIOLOGICAL PSYCHIATRY, 1995, 38 (11) : 742 - 746
  • [34] Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder(OCD): behavioral and biological results
    Broocks, A
    Pigott, TA
    Hill, JL
    Canter, S
    Grady, TA
    L'Heureux, F
    Murphy, DL
    [J]. PSYCHIATRY RESEARCH, 1998, 79 (01) : 11 - 20
  • [35] Reversible inhibitors of monoamine oxidase A in anxiety disorders
    Buller, R
    [J]. CLINICAL NEUROPHARMACOLOGY, 1995, 18 : S38 - S44
  • [36] Nociceptin/orphanin FQ receptor ligands
    Calo, G
    Bigoni, R
    Rizzi, A
    Guerrini, R
    Salvadori, S
    Regoli, D
    [J]. PEPTIDES, 2000, 21 (07) : 935 - 947
  • [37] Pharmacology of nociceptin and its receptor: a novel therapeutic target
    Calo, G
    Guerrini, R
    Rizzi, A
    Salvadori, S
    Regoli, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (07) : 1261 - 1283
  • [38] Anxiolytic-like profile of p-MPPI, a novel 5HT(1A) receptor antagonist, in the murine elevated plus-maze
    Cao, BJ
    Rodgers, RJ
    [J]. PSYCHOPHARMACOLOGY, 1997, 129 (04) : 365 - 371
  • [39] Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice .2. WAY 100635, SDZ 216-525 and NAN-190
    Cao, BJ
    Rodgers, RJ
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 58 (02) : 593 - 603
  • [40] Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice .1. Pindolol enantiomers and pindobind 5-HT1A
    Cao, BJ
    Rodgers, RJ
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 58 (02) : 583 - 591